Eventide Asset Management’s TG Therapeutics TGTX Stock Holding History

Eventide Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-716,414	Closed	-$21.4M	–	304
2025 Q4	$21.4M	Sell	716,414 -238,117	-25%	-$7.78M	0.33%	101
2025 Q3	$34.5M	Hold	954,531	–	–	0.57%	67
2025 Q2	$34.4M	Buy	954,531 +235,717	+33%	+$8.78M	0.6%	57
2025 Q1	$28.3M	Hold	718,814	–	–	0.56%	64
2024 Q4	$21.6M	Hold	718,814	–	–	0.39%	85
2024 Q3	$16.8M	Hold	718,814	–	–	0.29%	99
2024 Q2	$12.8M	Hold	718,814	–	–	0.22%	114
2024 Q1	$10.9M	Buy	718,814 +279,340	+64%	+$4.45M	0.17%	120
2023 Q4	$7.51M	Buy	+439,474	New	+$5.11M	0.12%	130
2017 Q1	–	Sell	-537,600	Closed	-$2.5M	–	128
2016 Q4	$2.5M	Hold	537,600	–	–	0.16%	92
2016 Q3	$4.16M	Hold	537,600	–	–	0.25%	73
2016 Q2	$3.26M	Hold	537,600	–	–	0.2%	81
2016 Q1	$4.58M	Hold	537,600	–	–	0.26%	79
2015 Q4	$6.41M	Buy	537,600 +161,800	+43%	+$2.04M	0.32%	76
2015 Q3	$3.79M	Buy	375,800 +104,700	+39%	+$1.56M	0.22%	84
2015 Q2	$4.5M	Buy	271,100 +88,100	+48%	+$1.4M	0.24%	78
2015 Q1	$2.83M	Buy	183,000 +28,000	+18%	+$424K	0.21%	89
2014 Q4	$2.46M	Hold	155,000	–	–	0.27%	74
2014 Q3	$1.65M	Buy	155,000 +20,000	+15%	+$185K	0.23%	79
2014 Q2	$1.27M	Buy	+135,000	New	+$863K	0.17%	92

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Eventide Asset Management's TGTX Position: Q1 2026 in Review

Eventide Asset Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 716,414 shares — an estimated $21.4M sold.

Eventide Asset Management first reported a position in TGTX in Q2 2014 and held it in 20 quarters. The position peaked at $34.5M in Q3 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Eventide Asset Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Eventide Asset Management sold 716,414 TG Therapeutics shares in Q1 2026, an estimated $21.4M.
Eventide Asset Management first reported a position in TG Therapeutics in Q2 2014 and held it in 20 quarters.
Eventide Asset Management's TG Therapeutics position peaked at $34.5M in Q3 2025.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.